Navigation Links
Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
Date:8/31/2009

NEW HAVEN, Conn., Aug. 31 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, today announced that one of its discovery-stage programs has yielded several computationally designed series of chemically unique compounds demonstrating efficacy in the treatment of infection in animal models.

The Rx-04 discovery program is focused on the development of novel classes of antibiotics active against serious, rapidly emerging multi-drug resistant Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. The company has built five chemical scaffolds, some of which have demonstrated activity against both Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Data from an earlier, related program will be presented during a poster sessions at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

"In less than one year, our structure and computationally driven research engine has engineered a variety of new lead scaffolds that appear to exhibit promising activity in mice, good drug-like properties and good safety in early tests, in addition to varied profiles against MDR gram-negative pathogens in vitro," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "The success we've seen to date with our later clinical stage antibiotic compounds, radezolid and delafloxacin, along with the immense progress made on the Rx-04 program, underscores the strength and diversity of the growing Rib-X pipeline."

About Rx-04

The Rx-04 program employs a de novo approach to develop novel antibiotics
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
3. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
4. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... operating officer and president, has resigned, effective July 31, ... consultant going forward on special projects. His resignation is ... this position since September 2013. On an interim basis, ... , who has been Neogen,s chief executive officer since ...
(Date:7/18/2014)... 18, 2014 Global biotechnology company ... offices in Cambridge, MA, announces the launch of ... Software product that leverages the power of Next ... MiSeq sequencing platform. The assay and software have ... of Philadelphia (CHOP) and will include a new ...
(Date:7/18/2014)... MA (PRWEB) July 18, 2014 Provia ... to its growing Advisory Board. Dr. Vaught has ... for over 20 years. As one of the ... Biological and Environmental Repositories - in 1999, he served ... is again president-elect. , In 2005, Dr. Vaught began ...
Breaking Biology Technology:Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3
... TORONTO, Sept. 20 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) ... Endotoxin,Activity Assay, a rapid diagnostic product for sepsis, ... division of the Italian,Menarini Group. Sepsis is the ... 60,000 victims each year. The treatment of severe ...
... Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company ... President and CEO,David J. Mazzo, Ph.D., will present a ... Thursday, September 27, 2007 at 10:00 a.m.,Eastern, in the ... York City. A live webcast of this presentation ...
... Sept. 20 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... commercializing proprietary product candidates for the treatment,of cancer ... Levine,ADVENTRX,s chief executive officer, is scheduled to present ... September 27th, 2007 at 8:00 a.m.,Eastern Time. The ...
Cached Biology Technology:Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany 2ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference 2
(Date:7/21/2014)... there are reasons mammoths and mastodons could have been ... research from the University of Cincinnati, the famously fuzzy ... before it was trendy at the end of ... Crowley, an assistant professor of geology and anthropology, shows ... likely were year-round residents and not nomadic migrants as ...
(Date:7/21/2014)... water and save on your utility bill? A paper ... the current issue of the journal Environment ... Effective Actions U.S. Households Can Take to Curb Water ... by simple actions such as installing more efficient appliances ... suggestions may be familiar, the researchers are the first ...
(Date:7/21/2014)... Medicine-led study suggests that parents of obese children often ... childhood weight gain or the importance of daily physical ... , The study is published online in the ... , "Parents have a hard time changing their child,s ... Rhee, MD, and an assistant adjunct professor in the ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Researchers provide guide to household water conservation 2Researchers provide guide to household water conservation 3Parents rank their obese children as 'very healthy' 2
... Oct. 1, 2013  Pfenex Inc. today announced that the ... Biomedical Advanced Research and Development Authority (BARDA), has modified ... with the existing Pfenex contractual relationship begun in July, ... funding to support the development of a next generation ...
... October 1, 2013 -- Resveratrol, a naturally occurring polyphenol ... peanuts, and found in red wine, has been touted ... antioxidant properties. This has been supported by some experimental ... new study using two multiple sclerosis (MS) models published ...
... , Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a ... drug development services to industry, announced today that they ... an investigational medication for Type 2 Diabetes Mellitus.  The ... tolerability of multiple daily doses of the investigational medication ...
Cached Biology News:Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 2Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 2Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 3Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... H2OBIT is a fully licensed, high throughput, water ... of up to 24 microplates. This equates to ... ,A robotic arm rapidly transfers a basket ... temperature ramping times that are considerably faster than ...
... used gasketed gel trays. Turn the tray 90 degrees ... back and run the gel - its as simple ... tray is UV transparent. Each tray accommodates two comb ... one in the center. This allows you the option ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: